Helus Pharma (NASDAQ: HELP) announced that results from a phase 2a randomized, placebo-controlled trial of SPL026 for major depressive disorder ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE